Mukesh Harisinghani, MD

Mukesh Harisinghani, MD

Harvard Medical School

Boston, Massachusetts

Dr. Mukesh Harisinghani is a Professor of Radiology at Harvard Medical School, as well as Director of Abdominal MRI and of the Clinical Discovery Program at the Massachusetts General Hospital in Boston, Massachusetts. In addition, he is also the Section Editor for GU Radiology for the American Journal of Roentgenology (AJR). He completed his residency and Clinical Fellowship in Abdominal Imaging & Intervention at Massachusetts General Hospital and has been on faculty in the Abdominal Section since 2001. Dr. Harisinghani’s research interests include MRI applications in body imaging, genitourinary radiology, and translational molecular imaging. His clinical expertise is in MR applications within the abdomen and pelvis. He has authored or coauthored over 150 scientific papers and has edited 5 books in these areas.

Disclosures:

Talks by Mukesh Harisinghani, MD

Prostate Imaging Elevated By Deep Learning

Mukesh Harisinghani, MD, Director of Abdominal MRI at Massachusetts General Hospital and Professor of Radiology at Harvard Medical School in Boston, Massachusetts, discusses how deep learning algorithms can improve the efficiency and accuracy of prostate cancer imaging. He highlights the importance of widespread prostate cancer screening, observing that every 3 minutes, a man is diagnosed with prostate cancer, and every 17 minutes, a man dies of prostate cancer. Dr. Harisinghani notes that patients want to get a multiparametric (mp)MRI if there is a clinical suspicion of prostate cancer and, if negative, avoid a biopsy in order to prevent unnecessary intervention and avoid cost. Because this is such a widespread need and mpMRIs are relatively time-consuming, he argues there is a need to figure out how to reduce scan time and not lose accuracy. Dr. Harisinghani explains that the two main time sinks in prostate mpMRI are T2-weighted imaging and diffusion-weighted imaging (DWI). He then demonstrates how deep learning reconstruction using software like AIR Recon DL in all 3 planes leads to significant time gain for T2-weighted imaging. Dr. Harisinghani says that many might be hesitant to ‘skimp’ on DWI, since higher b value (which takes a longer time to attain) leads to better image quality. However, he argues that deep learning can reduce scan time without reducing scan quality in DWI, and presents images comparing standard DWI and Air Recon DL to show the improved quality of the latter. Dr. Harisinghani concludes that a scan time of less than 10 minutes is not necessarily just a dream if you can apply Air Recon DL to both T2 and DWI.

Read More

Review of the Role of MRI-Targeted Biopsy vs Systematic Biopsy in Prostate Cancer

Mukesh Harisinghani, MD, Director of the Clinical Discovery Program Center for Molecular Imaging Research at the Massachusetts General Hospital, reviews recent research on the effectiveness of MRI-targeted biopsy as well as systematic biopsy on biopsy naive patients. Through the analysis of research results, he reveals that there is consistent evidence to support that combining the two techniques creates a substantial boost in detection rates. This boost has been proven to be a shift from a 21.4% detection rate in just systematic biopsy and 23.4% in just MRI-targeted biopsy to a detection rate of 27.7% when using combined techniques on biopsy naive patients.

Read More

Join the GRU Community

- Why Join? -